OpenLB
Open Library of Bioscience
Advanced Search
Trends in pharmacological sciences
Aug, 2010;31 (8): 381-90.

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Caline S Karam, Jacob S Ballon, Nancy M Bivens, Zachary Freyberg, Ragy R Girgis, José E Lizardi-Ortiz, Sander Markx, Jeffrey A Lieberman, Jonathan A Javitch
Author Information
  1. Caline S Karam: Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
PMID: 20579747 DOI: 10.1016/j.tips.2010.05.004

Abstract

Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia. While often effective at ameliorating psychosis, these drugs are largely ineffective at treating negative and cognitive symptoms. Increasing attention is being focused on the complex genetics of the illness and the signaling pathways implicated in its pathophysiology. We review targeted approaches for pharmacotherapy involving the glutamatergic, GABAergic and cholinergic pathways. We also describe several of the major genetic findings that identify signaling pathways representing potential targets for novel pharmacological intervention. These include genes in the 22q11 locus, DISC1, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway.

References

  1. Nat Neurosci. 2005 Nov;8(11):1586-94 [PMID: 16234811]
  2. Biochem Soc Trans. 2007 Apr;35(Pt 2):231-5 [PMID: 17371246]
  3. Cell. 2009 Mar 20;136(6):1017-31 [PMID: 19303846]
  4. Nat Rev Neurosci. 2008 Jun;9(6):437-52 [PMID: 18478032]
  5. Trends Genet. 2009 Dec;25(12):528-35 [PMID: 19883952]
  6. Am J Psychiatry. 2008 Jun;165(6):774 [PMID: 18519539]
  7. Lancet. 1990 Jul 7;336(8706):13-6 [PMID: 1973210]
  8. Biochem Pharmacol. 2009 Oct 1;78(7):880-8 [PMID: 19615981]
  9. Biol Psychiatry. 2006 Jul 15;60(2):132-40 [PMID: 16442083]
  10. Am J Hum Genet. 2003 Jul;73(1):152-61 [PMID: 12802784]
  11. Nat Genet. 2004 Feb;36(2):131-7 [PMID: 14745448]
  12. Front Neuroanat. 2009 Jul 02;3:9 [PMID: 19636386]
  13. Behav Brain Res. 1996 Jan;74(1-2):45-55 [PMID: 8851914]
  14. Neuron. 2004 Dec 16;44(6):987-96 [PMID: 15603741]
  15. Biol Psychiatry. 2008 Mar 1;63(5):449-57 [PMID: 17825267]
  16. Mol Psychiatry. 2007 Jan;12(1):74-86 [PMID: 17043677]
  17. Behav Brain Res. 2009 Dec 7;204(2):274-81 [PMID: 19379776]
  18. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):13-5 [PMID: 15274030]
  19. J Pharmacol Exp Ther. 2005 Apr;313(1):199-206 [PMID: 15608073]
  20. J Neurosci. 2003 Jul 16;23(15):6315-26 [PMID: 12867516]
  21. Am J Psychiatry. 2007 Oct;164(10):1593-602 [PMID: 17898352]
  22. Am J Med Genet. 1995 Apr 24;60(2):172-3 [PMID: 7485255]
  23. Behav Pharmacol. 2000 Jun;11(3-4):223-33 [PMID: 11103877]
  24. Neuroimage. 2008 Apr 1;40(2):712-718 [PMID: 18255317]
  25. Psychopharmacology (Berl). 2004 Jun;174(1):39-44 [PMID: 15205877]
  26. Neurosci Lett. 2005 Apr 29;379(1):32-6 [PMID: 15814194]
  27. Schizophr Res. 2008 Dec;106(2-3):89-107 [PMID: 18799287]
  28. Nat Med. 2007 Sep;13(9):1102-7 [PMID: 17767166]
  29. Nat Cell Biol. 2005 Dec;7(12):1167-78 [PMID: 16299498]
  30. Neuropsychopharmacology. 2009 Jun;34(7):1673-84 [PMID: 19145229]
  31. Nat Genet. 2004 Jul;36(7):725-31 [PMID: 15184899]
  32. Biol Psychiatry. 2008 Jan 1;63(1):17-23 [PMID: 17631867]
  33. J Neurochem. 2009 May;109 Suppl 1:133-8 [PMID: 19393019]
  34. Psychopharmacology (Berl). 2005 Apr;179(1):303-9 [PMID: 15309376]
  35. Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16859-64 [PMID: 12477929]
  36. J Neurosci. 2008 Jul 2;28(27):6872-83 [PMID: 18596162]
  37. Science. 2000 Nov 17;290(5495):1364-8 [PMID: 11082065]
  38. J Neurosci. 2006 Oct 4;26(40):10164-76 [PMID: 17021172]
  39. Am J Psychiatry. 2007 Aug;164(8):1269 [PMID: 17671295]
  40. Nat Neurosci. 2008 Nov;11(11):1302-10 [PMID: 18836441]
  41. Cereb Cortex. 2009 Mar;19(3):612-8 [PMID: 18632742]
  42. J Cell Biol. 2008 May 5;181(3):511-21 [PMID: 18458158]
  43. J Clin Psychiatry. 2007 Sep;68(9):1358-67 [PMID: 17915974]
  44. Neuron. 2000 Nov;28(2):325-34 [PMID: 11144342]
  45. Nat Neurosci. 2006 Dec;9(12):1477-8 [PMID: 17072305]
  46. Schizophr Bull. 2006 Jan;32(1):3-8 [PMID: 16306181]
  47. Nat Rev Neurosci. 2002 Oct;3(10):791-802 [PMID: 12360323]
  48. Nat Genet. 1999 Apr;21(4):434-9 [PMID: 10192398]
  49. Mol Psychiatry. 2007 Mar;12(3):232-46 [PMID: 17146471]
  50. Nat Genet. 2008 Jul;40(7):880-5 [PMID: 18511947]
  51. Int Rev Neurobiol. 2007;78:193-223 [PMID: 17349862]
  52. Cell. 2005 Jul 29;122(2):261-73 [PMID: 16051150]
  53. Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15873-8 [PMID: 19805229]
  54. Mol Psychiatry. 2008 Sep;13(9):873-7 [PMID: 18195713]
  55. J Mol Neurosci. 2005;25(3):225-38 [PMID: 15800376]
  56. Pharmacopsychiatry. 2008 Sep;41 Suppl 1:S51-9 [PMID: 18756421]
  57. Am J Psychiatry. 2008 Dec;165(12):1585-93 [PMID: 18923067]
  58. Mol Cell Neurosci. 2004 Jan;25(1):42-55 [PMID: 14962739]
  59. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83 [PMID: 19765575]
  60. J Pharmacol Exp Ther. 2006 Jul;318(1):173-85 [PMID: 16608916]
  61. Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13009-14 [PMID: 11069295]
  62. Biol Psychiatry. 2008 Jan 1;63(1):9-12 [PMID: 17659263]
  63. Am J Psychiatry. 2008 Aug;165(8):1033-9 [PMID: 18593778]
  64. Proc Natl Acad Sci U S A. 2008 May 13;105(19):7076-81 [PMID: 18458327]
  65. J Neurochem. 2008 Dec;107(5):1188-95 [PMID: 18957051]
  66. Science. 1998 Aug 28;281(5381):1349-52 [PMID: 9721099]
  67. J Biol Chem. 2004 Jul 2;279(27):28531-8 [PMID: 15123709]
  68. Nature. 2010 Apr 1;464(7289):763-7 [PMID: 20360742]
  69. Pediatrics. 2003 Jul;112(1 Pt 1):101-7 [PMID: 12837874]
  70. Cancer Res. 2001 Mar 1;61(5):1810-5 [PMID: 11280728]
  71. Neuropsychopharmacology. 1988 Sep;1(3):179-86 [PMID: 3075131]
  72. Arch Neurol. 2006 Oct;63(10):1372-6 [PMID: 17030651]
  73. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13656-61 [PMID: 18768802]
  74. Schizophr Res. 2009 May;110(1-3):149-55 [PMID: 19251401]
  75. Nat Genet. 2008 Jul;40(7):827-34 [PMID: 18583979]
  76. Biol Psychiatry. 2004 May 15;55(10):981-8 [PMID: 15121481]
  77. Mol Psychiatry. 2008 Nov;13(11):1054-9 [PMID: 17925794]
  78. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3717-22 [PMID: 11891283]
  79. Am J Psychiatry. 2003 Apr;160(4):636-45 [PMID: 12668349]
  80. Trends Neurosci. 2009 Sep;32(9):485-95 [PMID: 19712980]
  81. Biochem Soc Trans. 2009 Feb;37(Pt 1):308-12 [PMID: 19143653]
  82. Trends Pharmacol Sci. 2007 Apr;28(4):166-72 [PMID: 17349698]
  83. Biol Psychiatry. 2008 Jan 1;63(1):6-8 [PMID: 18082555]
  84. Mol Psychiatry. 2008 Jan;13(1):36-64 [PMID: 17912248]
  85. Mol Psychiatry. 1997 May;2(3):211-23 [PMID: 9152985]
  86. CNS Drug Rev. 2005 Winter;11(4):353-68 [PMID: 16614735]
  87. Schizophr Bull. 2009 May;35(3):549-62 [PMID: 19325164]
  88. Trends Neurosci. 2009 Jun;32(6):347-58 [PMID: 19409625]
  89. Mol Psychiatry. 2010 May;15(5):453-62 [PMID: 20424623]
  90. Am J Psychiatry. 2008 Aug;165(8):1040-7 [PMID: 18381905]
  91. Science. 2005 Feb 18;307(5712):1098-101 [PMID: 15718470]
  92. J Pharmacol Exp Ther. 2008 Apr;325(1):146-53 [PMID: 18199809]
  93. J Neurosci. 2000 Jan 1;20(1):485-94 [PMID: 10627624]
  94. Trends Pharmacol Sci. 2009 Jan;30(1):25-31 [PMID: 19058862]
  95. Cell Mol Neurobiol. 2007 Aug;27(5):609-39 [PMID: 17554626]
  96. Brain Res Mol Brain Res. 2004 Dec 20;132(2):95-104 [PMID: 15582150]
  97. J Cell Biol. 2002 Oct 14;159(1):23-8 [PMID: 12370247]
  98. Br J Pharmacol. 2008 Mar;153 Suppl 1:S428-37 [PMID: 18311157]
  99. Oncogene. 2008 Oct 27;27(50):6473-88 [PMID: 18955974]
  100. Neuron. 2001 Sep 13;31(5):841-51 [PMID: 11567621]
  101. Hum Mol Genet. 2003 Jul 1;12(13):1591-608 [PMID: 12812986]
  102. Am J Hum Genet. 2002 Oct;71(4):877-92 [PMID: 12145742]
  103. J Pharmacol Exp Ther. 2003 Jul;306(1):116-23 [PMID: 12660307]
  104. Am J Hum Genet. 2002 Dec;71(6):1296-302 [PMID: 12402217]

Grants

  1. T32 MH018870/NIMH NIH HHS
  2. R01 MH054137/NIMH NIH HHS
  3. DA022413/NIDA NIH HHS
  4. K08 MH090397/NIMH NIH HHS
  5. MH54137/NIMH NIH HHS
  6. K05 DA022413/NIDA NIH HHS

MeSH Term

Animals
Antipsychotic Agents
Dopamine D2 Receptor Antagonists
Drug Delivery Systems
Drug Design
Humans
Schizophrenia
Signal Transduction

Chemicals

Antipsychotic Agents
Dopamine D2 Receptor Antagonists
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Word Cloud

Created with Highcharts 10.0.0pathwaysdrugssignalingtargetsDopamineD2receptorantagonismunifyingpropertyantipsychoticuseschizophreniaofteneffectiveamelioratingpsychosislargelyineffectivetreatingnegativecognitivesymptomsIncreasingattentionfocusedcomplexgeneticsillnessimplicatedpathophysiologyreviewtargetedapproachespharmacotherapyinvolvingglutamatergicGABAergiccholinergicalsodescribeseveralmajorgeneticfindingsidentifyrepresentingpotentialnovelpharmacologicalinterventionincludegenes22q11locusDISC1Neuregulin1/ErbB4componentsAkt/GSK-3pathwaySignalingschizophrenia:emergingtherapeuticstrategies

Similar Articles

Cited By